Synendos Therapeutics Ag

Synendos Therapeutics AG is a biopharmaceutical company founded in April 2019 as a spin-off of the University of Bern. Synendos develops an innovative therapeutic approach based upon first-in-class inhibitors (small molecules) that modulate a new drug target (not yet published). The inhibitors were designed and developed at the University of Bern starting from an in silico screening of 12 million compounds which was followed by a thorough med chem programme in collaboration with a CRO. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the brain. Our mission is to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders.